India's Cipla has said in a filing with the Bombay Stock Exchange that it has completed a move forward with a joint venture in Algeria that will lead to the production of respiratory drugs there.
Sanofi's new CEO, Olivier Brandicourt, warned union workers in June that for the company to grow its French manufacturing operations, they needed to get more efficient, but he didn't say by how much. They need to improve a lot, it turns out.
Sanofi decided several years ago that it would shutter a plant in the Kansas City, MO, area after attempts to sell it turned up no deal. But with less than a year left before it is slated to close, the French drugmaker is giving the sales route another shot and has put the 690,000-square-foot facility back on the market.
Pfizer announced plans to sell a plant in India that was slated to be shuttered. But another Pfizer facility in Ireland that was once on the chopping block has not only been taken off the list of facilities no longer needed but is adding several dozen jobs.
Abbott Laboratories wlll expand its manufacturing, as well as other operations, in India, though a dollar amount was not given by the pharmaceutical giant.
Portuguese contract manufacturer Hovione is expanding its facility in New Jersey to meet increased commercial capacity demands from customers as well as increase its global development.
Despite news GlaxoSmithKline is dumping a satellite R&D facility in France and cutting 70 positions, the pharma giant says it will grow its manufacturing presence in the country.
Mayne Pharma established a U.S. beachhead three years ago when it picked up Metrics Contract Services and took over its campus in North Carolina. Now the Australian drugmaker will broaden its footprint with a new manufacturing plant that will significantly expand its capacity.
CDMO Aesica says one of its U.K. plants will receive electricity from a proposed biomass plant that is expected to reduce greenhouse gas emissions equal to removing 25,000 cars from the U.K.'s roads over 20 years.
Pfizer said two months ago that it would close a 55-year-old plant in Thane, India, that it no longer wanted. But someone sees some value in it, and the U.S. drugmaker now says the facility will be sold to an Indian operation for nearly $27 million.